A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
NCT06681623
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 55 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Neurology Center of New England P.C.
- Last updated on ClinicalTrials.gov
- November 18, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Neurology Center of New England P.C. · Foxborough, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.